BioCardia Files 8-K on Shareholder Votes and Other Events
Ticker: BCDA · Form: 8-K · Filed: May 21, 2024 · CIK: 925741
| Field | Detail |
|---|---|
| Company | Biocardia, Inc. (BCDA) |
| Form Type | 8-K |
| Filed Date | May 21, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 B |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, filing, financial-reporting
Related Tickers: BCDA
TL;DR
BioCardia filed an 8-K covering shareholder votes and other corporate updates.
AI Summary
BioCardia, Inc. filed an 8-K on May 20, 2024, reporting on matters submitted to a vote of security holders and other events. The filing also includes financial statements and exhibits. The company, formerly known as Tiger X Medical, Inc., is incorporated in Delaware and its fiscal year ends on December 31.
Why It Matters
This filing provides updates on corporate actions and financial reporting, which are crucial for investors to understand the company's governance and financial health.
Risk Assessment
Risk Level: low — This is a routine filing reporting on corporate events and financial statements, not indicating immediate financial distress or significant new risks.
Key Players & Entities
- BioCardia, Inc. (company) — Registrant
- Tiger X Medical, Inc. (company) — Former company name
- May 20, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
FAQ
What specific matters were submitted to a vote of BioCardia's security holders?
The filing indicates that matters were submitted to a vote of security holders, but the specific details of these matters are not provided in the excerpt.
What are the 'Other Events' reported in this 8-K filing?
The filing lists 'Other Events' as a category, but the specific nature of these events is not detailed in the provided text.
When is BioCardia's fiscal year end?
BioCardia's fiscal year ends on December 31.
What was BioCardia, Inc. previously named?
BioCardia, Inc. was formerly known as Tiger X Medical, Inc.
In which state is BioCardia, Inc. incorporated?
BioCardia, Inc. is incorporated in Delaware.
Filing Stats: 752 words · 3 min read · ~3 pages · Grade level 10.9 · Accepted 2024-05-21 17:00:52
Key Financial Figures
- $0.001 B — ich registered Common Stock, par value $0.001 BCDA The Nasdaq Capital Market Warrant
Filing Documents
- bcda20240520_8k.htm (8-K) — 45KB
- ex_677889.htm (EX-99.1) — 11KB
- 0001437749-24-017856.txt ( ) — 207KB
- bcda-20240520.xsd (EX-101.SCH) — 4KB
- bcda-20240520_def.xml (EX-101.DEF) — 13KB
- bcda-20240520_lab.xml (EX-101.LAB) — 17KB
- bcda-20240520_pre.xml (EX-101.PRE) — 13KB
- bcda20240520_8k_htm.xml (XML) — 5KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On May 20, 2024, BioCardia, Inc. (the "Company") held its Annual Meeting. Present at the Annual Meeting in person or by proxy were holders of 15,526,978 shares of the Company's common stock, representing 57.79% of the voting power of the shares of the Company's common stock as of April 15, 2024, the record date for the Annual Meeting, and constituting a quorum for the transaction of business. The matters before the Annual Meeting are described in more detail in the Company's definitive proxy statement filed with the United States Securities and Exchange Commission on April 15, 2024. Proposal 1 – Election of Directors . The following nominees were elected as Class II directors to serve until the 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified: Nominee Votes For Withheld Broker Non-votes Jim Allen 9,333,963 643,999 5,549,016 Andrew Blank 8,292,067 1,685,895 5,549,016 Proposal 2 – Ratification of the Appointment of Independent Registered Public Accounting Firm. The appointment of PKF San Diego, LLP as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2024, was ratified. Votes For Votes Against Abstentions Broker Non-votes 15,278,425 124,185 124,368 --- Proposal 3 – Approval, on an Advisory Basis, of the Company ' s Executive Compensation . The Company's executive compensation was approved on an advisory basis. Votes For Votes Against Abstentions Broker Non-votes 8,049,847 637,260 1,290,855 5,549,016 Proposal 4 – Approval of an amendment of the amended and restated certificate of incorporation to effect a reverse stock split of the Company ' s issued common stock, at a ratio of 1-for-2 to 1-for-20, to be determined in the sole discretion of the Company ' s board of directors, and if such reverse stock split is effected, a reduction in the number of authorize
01 Other Events
Item 8.01 Other Events. On May 21, 2024, the Company issued a press release announcing the Reverse Stock Split. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 104 BioCardia, Inc. press release dated May 21, 2024 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOCARDIA, INC. /s/ Peter Altman, Ph.D. Peter Altman, Ph.D. President and Chief Executive Officer Date: May 21, 2024